Published in N Engl J Med on February 02, 1989
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A (1989) 3.26
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
Molecular diagnosis of herpes simplex virus infections in the central nervous system. J Clin Microbiol (1999) 2.21
Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A (1991) 2.12
Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother (1998) 1.89
Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol (2004) 1.56
"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev (1994) 1.54
Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1994) 1.50
Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J Virol (1997) 1.44
Recent advances in management of genital herpes. Can Fam Physician (2000) 1.44
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A (1995) 1.41
Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol (1998) 1.37
Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc Natl Acad Sci U S A (1994) 1.33
Mutations in accessory DNA replicating functions alter the relative mutation frequency of herpes simplex virus type 1 strains in cultured murine cells. J Virol (1994) 1.27
A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant. Proc Natl Acad Sci U S A (1994) 1.26
Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother (1992) 1.23
The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol (2010) 1.12
In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1991) 1.10
Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus. Antimicrob Agents Chemother (1995) 1.05
Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother (1994) 1.03
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob Agents Chemother (1998) 1.03
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother (2002) 1.02
Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. Antimicrob Agents Chemother (1997) 1.01
Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol (2001) 1.00
Management of herpes simplex and varicella-zoster virus infections. West J Med (1997) 0.97
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother (1991) 0.97
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother (2009) 0.95
Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates. Graefes Arch Clin Exp Ophthalmol (1996) 0.93
Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev (1995) 0.92
Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus. Proc Natl Acad Sci U S A (1993) 0.89
Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96. J Virol (2001) 0.89
Application of real-time PCR for determination of antiviral drug susceptibility of herpes simplex virus. Antimicrob Agents Chemother (2002) 0.87
Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrob Agents Chemother (1995) 0.86
Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models. Antimicrob Agents Chemother (2000) 0.83
Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother (1993) 0.82
Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A. BMC Bioinformatics (2011) 0.81
The use of nerve growth factor in herpetic keratitis: a case report. J Med Case Rep (2007) 0.81
Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis. Antimicrob Agents Chemother (2002) 0.81
Pediatric human immunodeficiency virus infection. Clin Microbiol Rev (1996) 0.81
Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. J Virol (1992) 0.80
Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother (1991) 0.80
Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc Natl Acad Sci U S A (1991) 0.80
Houttuynia cordata targets the beginning stage of herpes simplex virus infection. PLoS One (2015) 0.79
Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses. Antimicrob Agents Chemother (2006) 0.79
The Clinical Implications of Reduced Viral Fitness. Curr Infect Dis Rep (2004) 0.78
Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother (1995) 0.77
Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother (1993) 0.77
Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management. Neurotherapeutics (2016) 0.77
Pitfalls in the management of herpes simplex virus encephalitis. BMJ Case Rep (2012) 0.76
Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: Four approved indications and 13 off-label uses. Can J Infect Dis (2003) 0.75
Antiviral drug resistance. BMJ (1996) 0.75
Therapy for genital herpes in immunocompromised patients: a national survey. The Herpes Simplex Advisory Panel. Genitourin Med (1997) 0.75
Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers. Br J Ophthalmol (1996) 0.75
Long-term suppression of severe recurrent genital herpes simplex infections with oral acyclovir: a dose-titration study. Genitourin Med (1990) 0.75
Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids. BMC Complement Altern Med (2017) 0.75
Drug-resistant herpesviruses: should we look for them? Eur J Clin Microbiol Infect Dis (1998) 0.75
Clinical management of the complications of HIV infection. J Gen Intern Med (1991) 0.75
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (2008) 6.50
Comparison of HIV-antibody prevalence in patients consenting to and declining HIV-antibody testing in an STD clinic. JAMA (1988) 6.14
A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science (2000) 5.52
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med (1992) 4.71
Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1984) 4.64
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med (1996) 4.28
An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer (1978) 3.82
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med (1998) 3.81
A nondefective (competent) adenovirus-SV40 hybrid isolated from the AD.2-SV40 hybrid population. Proc Natl Acad Sci U S A (1969) 3.81
The natural history of Hendra and Nipah viruses. Microbes Infect (2001) 3.77
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother (1979) 3.61
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med (1988) 3.49
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol (2008) 3.31
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med (1999) 3.30
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med (1995) 3.28
Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med (1981) 3.25
Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet (1985) 2.88
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. V. Isolation of additional hybrids which differ in their simian virus 40-specific biological properties. J Virol (1973) 2.87
Prospective study of chlamydial infection in neonates. Lancet (1979) 2.80
Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol (1996) 2.75
Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A (1980) 2.72
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Development of allergy in children. I. Association with virus infections. J Allergy Clin Immunol (1979) 2.48
High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.47
Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect (2006) 2.45
Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol (1995) 2.44
Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis (1991) 2.43
Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA (1987) 2.43
Maternal smoking, alcohol drinking, caffeine consumption, and fetal growth: results from a prospective study. Epidemiology (1995) 2.41
Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med (1982) 2.37
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis (2000) 2.36
Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med (1986) 2.36
Influence of immunological factors in respiratory syncytial virus disease. Arch Environ Health (1970) 2.30
Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol (1999) 2.29
Comparison of direct immunofluorescence and direct immunoperoxidase procedures for detection of herpes simplex virus antigen in lesion specimens. J Clin Microbiol (1983) 2.27
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS. Rev Infect Dis (1987) 2.19
British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax (2013) 2.17
Interferon therapy for condylomata acuminata. N Engl J Med (1986) 2.16
Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 2.14
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med (2001) 2.13
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med (1991) 2.12
Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med (1994) 2.12
Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A (1991) 2.12
Physical and genetic analysis of the herpes simplex virus DNA polymerase locus. Virology (1980) 2.11
NHLBI workshop summary. Pulmonary complications of the acquired immunodeficiency syndrome: an update. Report of the second National Heart, Lung and Blood Institute workshop. Am Rev Respir Dis (1987) 2.09
Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res (1975) 2.02
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VI. Characterization of the DNA from five nondefective hybrid viruses. J Virol (1973) 2.01
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med (1993) 1.99
Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med (1985) 1.99
Mild cognitive impairment in prediagnosed Huntington disease. Neurology (2010) 1.96
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA (1984) 1.94
Review of University of British Columbia Family Practice Resident Research Projects 1990-1997. Fam Med (1999) 1.94
Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol (1998) 1.94
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1991) 1.89
Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med (1990) 1.89
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS (1999) 1.86
Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocyte/macrophages. AIDS Res Hum Retroviruses (1987) 1.86
Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J (1988) 1.80
Respiratory syncytial virus neutralizing activity in nasal secretions following natural infection. Proc Soc Exp Biol Med (1969) 1.79
Temperature-sensitive mutants of influenza virus. I. Behavior in tissue culture and in experimental animals. J Infect Dis (1971) 1.78
Mechanisms of platelet aggregation by viridans group streptococci. Infect Immun (1987) 1.77
Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis (1993) 1.76
Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA (1988) 1.76
Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol (1990) 1.72
Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis (1982) 1.72
Pulmonary infectious complications of human immunodeficiency virus infection. Part I. Am Rev Respir Dis (1990) 1.71
The essential 65-kilodalton DNA-binding protein of herpes simplex virus stimulates the virus-encoded DNA polymerase. J Virol (1989) 1.67
Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis (1985) 1.66
The natural history of recurrent facial-oral infection with herpes simplex virus. J Infect Dis (1978) 1.65
Bronchial hyperresponsiveness in normal subjects during attenuated influenza virus infection. Am Rev Respir Dis (1991) 1.64
The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg (1980) 1.63
Risk of infection after penetrating abdominal trauma. N Engl J Med (1984) 1.60
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. 3. Base composition, molecular weight, and conformation of the Ad2+ND genome. J Virol (1971) 1.59
Cefoxitin: clinical evaluation in thirty-eight patients. Antimicrob Agents Chemother (1977) 1.58
Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication. Antimicrob Agents Chemother (1984) 1.58
Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol (2009) 1.57
Persistence of high-risk sexual activity among homosexual men in an area of low incidence of the acquired immunodeficiency syndrome. Sex Transm Dis (1987) 1.57
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis (1997) 1.56
Experimental asbestosis with four types of fibers: importance of small particles. Ann N Y Acad Sci (1965) 1.55
Pulmonary infectious complications of human immunodeficiency virus infection. Part II. Am Rev Respir Dis (1990) 1.55
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis (2000) 1.54
Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis (1996) 1.53